Stocks fell Tuesday as recent gains boosted by easing trade tensions propel stocks near their peak, ending the S&P 500's six-day winning streak. The broader market slipped about 0.4%, while the Dow Jones Industrial Average lost more than 100 points and the Nasdaq Composite closed 0.4% lower.
Here's how the market settled on Tuesday:
S&P 500 Index
Dow Jones Industrial Average
Nasdaq Composite Index
Market sentiment has remained positive since the United States and China reached a temporary deal to scale down tariffs imposed on each nation, pushing the S&P 500 to multiple several-session winning streaks over the past five weeks and bringing the index to about 3% from its record high; the S&P briefly reached a bear market in April after President Donald Trump announced his initial tariff policies.
However, uncertainty still remains around the impacts of tariffs on the economy, even at their lower levels. On Friday, Moody's Ratings downgraded its U.S. sovereign credit rating to align with ratings from peers Standard and Poor's and Fitch Ratings. The decision offers another sign that borrowing costs are likely to remain high across the U.S. economy as price pressures from tariffs take effect.
Consumer bellwether Home Depot
Chief Financial Officer Richard McPhail told multiple news outlets on Tuesday that Home Depot does not plan to increase prices in response to tariffs. Last week, Walmart
"On tariffs -- it's important to remember that more than 50 percent of our purchases are sourced in the United States. We've been working with our vendors for years to further diversify our global supply chain," McPhail told Yahoo Finance in a statement. "During that time, the vast majority of our supplier partners diversified their sourcing strategies across several countries," added that Home Depot expects that "no single country outside of the United States will represent more than 10% of our purchases" a year from now.
In the News:
Warby Parker
"The companies are working closely on the development of future smart glasses and intend to launch a series of products over time," the company said in a release. "The partners' first line of intelligent eyewear, planned to launch after 2025, will incorporate multimodal AI with prescription and non-prescription lenses."
Shares of COVID vaccine leaders Moderna
"The FDA's new Covid-19 philosophy represents a balance of regulatory flexibility and a commitment to gold-standard science," the agency said in the paper. "The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at low risk."
Looking Ahead:
Investors will turn their attention towards more key retail earnings reports from Lowe's
